Trial reportThe pharmacogenomics journal2002
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.
Trial report in The pharmacogenomics journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 72 citations in OpenAlex.
- Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2021Review
- Response to Fluvoxamine in the Obsessive-Compulsive Disorder Patients: Bayesian Ordinal Quantile Regression.Clinical practice and epidemiology in mental health : CP & EMH · 2021Article
- Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders.International clinical psychopharmacology · 2020Review
- Impact of serotonin transporter gene on rTMS augmentation of SSRIs for obsessive compulsive disorder.Neuropsychiatric disease and treatment · 2019Article
- Whole-genome association analysis of treatment response in obsessive-compulsive disorder.Molecular psychiatry · 2016Article
- Functional Evaluations of Genes Disrupted in Patients with Tourette's Disorder.Frontiers in psychiatry · 2016Review
- Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder.The pharmacogenomics journal · 2013Article
- The genomics of selection in dogs and the parallel evolution between dogs and humans.Nature communications · 2013Article
- Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.Pharmacogenomics · 2012Review
- Association of SLC6A4 variants with obsessive-compulsive disorder in a large multicenter US family study.Molecular psychiatry · 2011Article
- Genetics of obsessive-compulsive disorder.The Psychiatric clinics of North America · 2010Review
- Drug treatment of obsessive-compulsive disorder.Dialogues in clinical neuroscience · 2010Review
- Autism spectrum and obsessive-compulsive disorders: OC behaviors, phenotypes and genetics.Autism research : official journal of the International Society for Autism Research · 2009Review
- Pharmacogenetics of anxiolytic drugs.Journal of neural transmission (Vienna, Austria : 1996) · 2009Review
- The genetics of obsessive-compulsive disorder and Tourette's syndrome: what are the common factors?Current psychiatry reports · 2009Review
- How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.Neuropharmacology · 2008Review
- Genetic variation and shared biological susceptibility underlying comorbidity in neuropsychiatry.Neurotoxicity research · 2007Review
- The genetic studies of obsessive-compulsive disorder and its future directions.Yonsei medical journal · 2006Review
- Understanding obsessive-compulsive disorder: focus on decision making.Neuropsychology review · 2006Review
- Obsessive-compulsive disorder phenotypes: implications for genetic studies.Molecular psychiatry · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype interaction for both YBOCS total scores and compulsion scores was found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.